About Us

VBL is a publicly traded (NASDAQ: VBLT), clinical stage biotechnology company committed to the discovery, development and commercialization of next-generation, targeted medicines for difficult-to-treat medical conditions.
Our goal is to develop and provide safe, effective and life-improving medicines to people living with cancer and immune-inflammatory diseases.

Our expertise in human immunology and cancer led to the development of our proprietary gene-targeting and antibody technologies – the Vascular Targeting System (VTS™) and Monocyte Targeting Technology (MTT), which are designed to precisely address advanced cancers and immune-inflammatory diseases.

VBL’s lead oncology product candidate, ofra-vec (ofranergene obadenovec or VB-111) was developed utilizing the VTS™ platform and is an investigational, potentially first-in-class, targeted anti-cancer gene-therapy designed to treat a wide range of solid tumors.
OFRA-VEC IS CURRENTLY BEING STUDIED AS A TREATMENT IN COLORECTAL CANCER AND GLIOBLASTOMA.

In-House Manufacturing

VBL production technicians in blue and white lab hoodies standing next to large stainless steel bioreactors in a clean room.